RPI-GLYT2-82 | GLYT2 antagonist
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $85.00 | ||
| 25 mg | $315.00 |
RPI-GLYT2-82 is a reversible, allosteric antagonist (IC50 = 554 nM) of Glycine Transporter 2(GLYT2) with selectivity over GLYT1. It is also an antagonist of the serotonin receptor 5-HT2A (IC50 = 1.9 µM). RPI-GLYT2-82 displayed efficacy in the CCI and PSNL mouse models of neuropathic pain. It showed no addiction liability and had no on-target side effects.
References/Citations:
- Chater et al. (2026), A reversible allosteric inhibitor of GlyT2 for neuropathic pain without on-target side effects; Nat. Commun. 17 2828
- Cioffi et al. (2026), Identification of Non-competitive and Reversible Inhibitors of Glycine Transporter 2: A Promising Non-opioid Therapeutic Strategy for Neuropathic Pain; J. Med. Chem. 69 10278
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
RPI-GLYT2-82 is a reversible, allosteric antagonist (IC50 = 554 nM) of Glycine Transporter 2(GLYT2) with selectivity over GLYT1. It is also an antagonist of the serotonin receptor 5-HT2A (IC50 = 1.9 µM). RPI-GLYT2-82 displayed efficacy in the CCI and PSNL mouse models of neuropathic pain. It showed no addiction liability and had no on-target side effects.
References/Citations:
- Chater et al. (2026), A reversible allosteric inhibitor of GlyT2 for neuropathic pain without on-target side effects; Nat. Commun. 17 2828
- Cioffi et al. (2026), Identification of Non-competitive and Reversible Inhibitors of Glycine Transporter 2: A Promising Non-opioid Therapeutic Strategy for Neuropathic Pain; J. Med. Chem. 69 10278
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass